Deferasirox-Fe3-chelate-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEDeferasirox Fe3+ chelateCat. No.: HY-16564CAS No.: 554435-83-5分式: CHFeNO分量: 426.18作靶点: Others作通路: Others储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 50 mg/mL (117.32 mM; Need ultrasonic)

2、Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.3464 mL 11.7321 mL 23.4643 mL5 mM 0.4693 mL 2.3464 mL 4.6929 mL10 mM 0.2346 mL 1.1732 mL 2.3464 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验 请根据您的实验动物和给药式选择适当的溶解案，配制前请先配制澄清的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄清的储备液可以根据储存条件，适当保存；以下溶剂

3、前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.87 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (5.87 mM); Clear solutionBIOLOGICAL ACTIVITY1/2 Master of Small Molecules 您边的抑制剂师www.MedChemE物活性 Defera

4、sirox Fe3+ chelate服的铁螯合剂。体外研究 Deferasirox is the first oral medication approved in the USA for this purpose. The half-life of deferasirox isbetween 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to1 atom of iron which are subsequently eliminated by fec

5、al excretion. Its low molecular weight and highlipophilicity allows the drug to be taken orally unlike desferoxamine which has to be administered by IV route(intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron fromcells (cardiac myocytes and hepatocytes

6、) as well as removing iron from the blood.REFERENCES1. Yang LP, Keam SJ, Keating GM. Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs.2007;67(15):2211-30.2. Kontoghiorghes GJ. Introduction of higher doses of deferasirox: better efficacy but not effect

7、ive iron removal from the heart andincreased risks of serious toxicities. Expert Opin Drug Saf. 2010 Jul;9(4):633-41.3. Galanello R, Campus S, Origa R. Deferasirox: pharmacokinetics and clinical experience. Expert Opin Drug Metab Toxicol. 2012Jan;8(1):123-34.4. Donnelly JP, Lahav M. Deferasirox as a

8、djunctive therapy for mucormycosis. J Antimicrob Chemother. 2012 Mar;67(3):519-20.5. Lui GY, Obeidy P, Ford SJ et al. The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against HumanLung Tumor Xenografts and Molecular Mechanism of Action. Mol Pharmacol. 2012 Oct 16. Epub ahead of printMcePdfHeightCaution: Product has not been fully validated for medical application